Replies to post #224257 on Amarin Corp Plc (AMRN)

[veni vidi vici]

Regarding the tweet from AF...

Exerpt from the full pub:

The statistical interaction terms for heterogeneity for the comparisons of USA and non-USA patients were not significant for most endpoints, and therefore differences in efficacy outcomes for the USA patients are best viewed as qualitative and not quantitative. Nevertheless, the data are useful and provide reassurance that the results seen in the USA are at least as strong as the results seen outside the USA and in the trial overall.

[KCSVEN]

He wants to write about Adcom and get hits, he wants controversy and newsworthy tidbits form Adcom. I think it is settling in that this is going to be an Ascom void of controversy and negativity so he will do anything to get something stirred up.

[chas1232123]

Next they'll complain that half the results were below average.

[sts66]

What a lying POS moron - "US patients taking Vascepa showed a greater benefit than overall patient population in REDUCE-IT" does NOT mean "ex-US patients had a worse outcome", it means they had BETTER outcomes - less events.